Ahead of an upcoming PBAC stakeholder meeting on MS medicines, CEO Rohan Greenland outlines MS Australia’s key messages, including the importance of treatment choice and continued PBS access.
A public consultation is now open as part of a rapid review of PBS-listed medicines for relapsing-remitting MS. The MS community has an important opportunity to share their experiences and help ensure the lived experience of Australians with MS remains central to future PBS decisions.
MS Nurses Australasia and their invited presenters shared specialist expertise and insights on MS care at their 27th Annual Conference in August 2026 in Sydney.
Through the lens of living with MS or caring for someone with MS, MS Australia’s lived experience expert panellists Rachel Fallis and Rebecca Small contemplate a future where family screening for MS was available.
Carol Cooke AM PLY shares her MS diagnosis story and how she’s grown more comfortable with speaking up for herself in medical settings in the years since her diagnosis.
Australian research suggests some prescription medications may worsen sleep quality in people with MS. Better sleep may improve MS symptoms, work productivity and overall quality of life.
Further details have now been announced about the Pharmaceutical Benefits Advisory Committee’s rapid review of medicines listed on the Pharmaceutical Benefits Scheme (PBS) for relapsing-remitting multiple sclerosis.
Susan reflects on her journey with MS from a young age, her diagnosis story and the importance of building a strong support network.
The research, funded through MS Australia’s mid-year grants round and based at The Florey Institute of Neuroscience and Mental Health, will investigate how the brain naturally produces myelin, the protective coating around nerve fibres that is damaged by MS.
